Moderna is still preparing for the launch of its COVID-19 vaccine mRNA-1273 – assuming phase 3 trials go to plan – but has already received $1.1 billion in deposits for the shot. The figure was revealed by CEO Stéphane Bancel in Moderna’s third-quarter results call… Read More »Moderna banks $1.1bn in COVID-19 vaccine deposits, signs Japan supply deal
Health secretary Matt Hancock has ‘overplayed his hand’ by pushing for total use of remote consultations, according to the chair of the RCGP, who insisted that face-to-face consultations will always be needed to offer ‘best patient care’.
Gilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment with its Veklury antiviral, and its latest financial results reveal the benefit of that achievement. The US drugmaker sold $873 million-worth of Veklury (remdesivir) in the three… Read More »Gilead Q3 revenue rise bolstered by $873m Veklury sales
CMS’ interim rule states that Medicare will cover Covid-19 vaccines approved by the FDA, including those receiving emergency use authorization, in a reversal from its usual policy. The vaccine will be made available at no cost to Medicare beneficiaries.
Deferred care because of Covid-19 will lead to additional stress on the healthcare system in the very near future and here’s how insurers can manage it.
GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the second as a result of the COVID-19 pandemic, putting it back on course to meet the lower end of earnings guidance for the year. The bounce-back wasn’t… Read More »Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares
The US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million if the drug gets Emergency Use Authorisation (EUA) – despite the fact its effectiveness has been called into question. The initial agreement is for delivery over the… Read More »US buys Lilly COVID antibody, as effectiveness questions remain
Doctors have urged the government to divert hundreds of millions of pounds from the ‘failing, privatised national test and trace’ service to local primary care, NHS labs and public health.
Doctors have urged the government to divert hundreds of millions of pounds from the ‘failing, privatised national test and trace’ service to local primary care, NHS labs and public health.
Even though Covid-19 is distinct from any health crisis the country has previously faced, assessing U.S. public health strategies during past crises can provide insight into what has contributed to a more or less equitable response.
Russia’s sovereign wealth fund has filed applications with the World Health Organization (WHO) that if approved could see the Sputnik V coronavirus vaccine backed for use in many countries around the world. The applications are for two WHO mechanisms, aimed at providing a route to… Read More »Russia’s COVID-19 vaccine filed with WHO, as MHRA reviews Moderna shot
More than 200 GPs a month are seeking mental health support as COVID-19 drives up pressure on the NHS – and demand for help is rising fastest among doctors in primary care, figures from a confidential support service suggest.
More than 200 GPs a month are seeking mental health support as COVID-19 drives up pressure on the NHS – and demand for help is rising fastest among doctors in primary care, figures from a confidential support service suggest.
Eli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run by the US National Institute of Allergy and Infectious Diseases (NIAID), as results to date suggest it is unlikely to be effective. The ACTIV-3 study was comparing… Read More »NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial
The post What’s in the air? Aerosol transmission drawing increased attention appeared first on Healthy Debate.
Vaccine being trialled by Oxford University and AstraZeneca offers hope for all age groups Coronavirus – latest updates See all our coronavirus coverage One of the world’s leading Covid-19 experimental vaccines produces an immune response in both older and young adults, raising hopes of a… Read More »Oxford Covid vaccine works in all ages, trials suggest
More than three in five GPs say they or clinical colleagues have been forced to self-isolate within the past fortnight, with many reporting reduced capacity and cancelled appointments at a time when workload is soaring.
More than three in five GPs say they or clinical colleagues have been forced to self-isolate within the past fortnight, with many reporting reduced capacity and cancelled appointments at a time when workload is soaring.
Moderna is close to completing its phase 3 trial of COVID-19 vaccine candidate mRNA-1273 after completing recruitment of the 30,000 subjects in the trial. It’s also revealed that more than 25,000 of them have already received the second dose of the shot in the COVE… Read More »Moderna nears COVID-19 vaccine finish line as it wraps up study enrolment
US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adverse reaction in one patient who received the shot. Separately, Johnson & Johnson has also announced it is resuming recruitment… Read More »AZ, J&J COVID-19 vaccine trials okay to restart in US
Pharmacy chain says £120 cost will be one of cheapest private tests available Coronavirus – latest updates See all our coronavirus coverage Boots is to offer a coronavirus testing service it says can return results from swab tests in only 12 minutes. The pharmacy chain… Read More »Boots to offer 12-minute Covid testing service within weeks
During the 40th week since the first coronavirus case appeared in the United States, worldwide cases surpassed the 41 million mark and U.S. cases are over 8 million and 223,000 deaths.
There is a surging demand for pre-sterilized surgical technologies at healthcare facilities because of the desire to both curb risk factors associated with Covid-19 at hospitals and also reduce the possibility of bacterial co-infections.
To keep critical revenue flowing, hospitals and ambulatory surgery centers need to resume elective surgeries and procedures as quickly as possible and mobile apps can help by giving patients and staff vital information, provide advance symptom screening and help providers reduce elective procedure no-shows through… Read More »Technology can ease pandemic challenges faced by hospitals, ambulatory surgery centers
This data note examines the status of U.S. global COVID-19 country, regional, and worldwide funding to assess how much has been committed to date and where it has been directed.
Gilead’s Veklury (remdesivir) has become the first COVID-19 drug approved in the US following a nod from the FDA. As an antiviral drug, remdesivir works to stop replication of SARS-CoV-2, the virus that causes COVID-19. Originally intended as a treatment for Ebola virus, remdesivir made… Read More »Gilead’s remdesivir finally gets US approval
A renewed interest in whether the BCG vaccine (for tuberculosis) could also have an application for COVID-19 has been on the rise, as evidenced by this recent Cell publication, the University of Exeter’s involvement in the BRACE Trial and ongoing general press coverage. Furthermore, the list of clinical trials focusing… Read More »BCG – COVID-19 Hackathon Challenge Now Extended Through End of Year
Is a century-old vaccine a ‘game-changer’ for COVID-19? Anita de Waard from Elsevier and Radoslav Kirkov from Estafet tells us how a hackathon is harnessing data science to look beyond the hype and seek definitive clinical evidence. Today, the notion of ‘data science’ has permeated… Read More »Data hackathon analyses truth behind TB vaccine and COVID-19
The Food and Drug Administration approved Gilead’s antiviral drug as the first treatment for Covid-19 but just last week a WHO report showed that the drug appeared to have little to no effect on hospitalized patients.
More than half of GPs say numbers of older patients coming forward with cancer symptoms remain low compared with pre-coronavirus levels, a poll reveals.
More than half of GPs say numbers of older patients coming forward with cancer symptoms remain low compared with pre-coronavirus levels, a poll reveals.
A new KFF analysis examines leading causes of death and mortality rates in the United States and comparable countries. The U.S. has a higher COVID-19 mortality rate than many of its peer countries, with COVID-19 ranking as the nation’s third-leading cause of death in 2020,… Read More »Analysis: COVID-19 Ranks as a Top 3 Leading Cause of Death in the U.S., Higher than in Almost All Other Peer Countries
A new KFF brief looks at where COVID-19 falls as a leading cause of death in the U.S. compared to similarly large and wealthy countries. The analysis finds that COVID-19 mortality rates are the third leading cause of death in the U.S., a ranking shared… Read More »The Pandemic’s Effect on the Widening Gap in Mortality Rate between the U.S. and Peer Countries
GPs and primary care teams should have played a key role in the UK’s efforts to test, track and trace coronavirus, according to a leading global health expert who has labelled the current system ‘a disaster and a national shame’.
GPs and primary care teams should have played a key role in the UK’s efforts to test, track and trace coronavirus, according to a leading global health expert who has labelled the current system ‘a disaster and a national shame’.
Roche may not be the first company that comes to mind for a COVID-19 treatment, but the Swiss firm is taking a big swing at the market to rival Gilead’s remdesivir. The company has joined forces with Atea Pharmaceuticals to develop, manufacture and distribute Atea’s… Read More »Roche to co-develop remdesivir rival in partnership with Atea
While there are encouraging signs of reimbursement falling in step with the move towards a more value-based healthcare system, what is needed now to further encourage healthcare innovators is to properly rationalize approval processes imposed by the FDA and CMS.
As the 2020 Election Day approaches, many candidates continue to focus on health care issues, including on the public health and economic response to COVID-19, the future of the Affordable Care Act, health care costs and abortion. To help reporters understand and cover these issues,… Read More »Health Policy Resources for Covering the 2020 Elections
GP practices across England are facing a significant loss of income as COVID-19 dries up key funding streams, accountants have warned, with some on track to lose more than £50,000 this financial year.
GP practices across England are facing a significant loss of income as COVID-19 dries up key funding streams, accountants have warned, with some on track to lose more than £50,000 this financial year.
In our latest article in the What HCPs Think series, CREATION.co’s Jamie Doggett analyses the social media activity of doctors to determine their views on how schools should operate during COVID-19. When and how schools should return was a big question for the UK during… Read More »What HCPs Think about schools reopening
The war of words between Donald Trump and his top infectious diseases expert Dr Anthony Fauci has intensified as the president’s handling of the coronavirus pandemic comes under increasing scrutiny. CNN reported that on a campaign call a “frustrated and at times foul-mouthed” Trump ranted… Read More »Trump launches tirade against NIAID chief Fauci as COVID-19 crisis escalates
This brief examines key policy challenges and issues related to distributing a COVID-19 vaccine in the U.S., including funding, supply and logistics, federal, state, and local authorities, insurance coverage, addressing racial and ethnic disparities, and communication and trust.
GPs have rebuffed suggestions that primary care networks (PCNs) are ‘best placed’ to run COVID-19 test and trace systems, but argue they should have greater involvement in testing.
GPs have rebuffed suggestions that primary care networks (PCNs) are ‘best placed’ to run COVID-19 test and trace systems, but argue they should have greater involvement in testing.
Pfizer now has hundreds of thousands of doses of BioNTech’s COVID-19 vaccine coming off the production line at a facility in Belgium, ready for delivery if it clears phase 3 testing. The output of the plant in Puurs should allow the partners to have 100… Read More »Pfizer ‘ready to roll’ if BioNTech COVID-19 shot is approved
The UK government has signed a contract to develop a controversial COVID-19 human challenge trial, where participants will be deliberately infected in a controlled environment with coronavirus to test whether a vaccine is effective. Contract research organisation (CRO) hVIVO, a subsidiary of Open Orphan, has… Read More »UK government signs contract for COVID-19 challenge trial
Employees at Nottingham head office say they were barred from toilets newly reserved for executives Coronavirus – latest updates See all our coronavirus coverage Boots roped off office toilets for executives during the pandemic, making it harder for ordinary employees to practise social distancing, the… Read More »Boots accused of harming social distancing by roping off HQ toilets
A wider range of healthcare workers will be allowed to administer flu and potential COVID-19 vaccines under laws introduced last week that aim to ease pressure on GPs during the pandemic.
Regular fliers are used to long queues to clear security – but a rigorous COVID-19 testing regime could be added to pre-flight checks backed by a digital “health passport” to prove passengers are free from the coronavirus. The UK is the latest country to test… Read More »UK trials digital ‘health passport’ to help borders reopen
Even a once bullish PM is now not so optimistic but there are promising signs of a vaccine on the horizon Coronavirus – latest updates See all our coronavirus coverage In March, Boris Johnson said we would turn the tide in 12 weeks and “send… Read More »Are we near to having a vaccine for Covid-19?
Total confirmed cases in the U.S. surpassed 7.9 million this week. There was an approximate increase of 373,800 confirmed cases between October 9 and October 15. Approximately 4,900 confirmed deaths in the past week brought the total in the United States to approximately 217,700.
Emails show senior managers ‘expecting’ attendance at Nottingham HQ despite big spike in local cases Coronavirus – latest updates See all our coronavirus coverage Boots told staff they were “encouraged” to come in to its headquarters in Nottingham, where Covid-19 infection rates are the highest… Read More »Boots bosses ‘encouraged’ staff to work at head office despite UK government advice
Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclinical testing. The French drugmaker’s Sanofi Pasteur vaccines division says it is planning a phase 1/2 trial of the… Read More »Sanofi preps trials of second COVID-19 shot, as Russia approves another
San Diego-based diagnostics startup Cue Health won a $481 million from the Department of Health and Human Services and the Department of Defense to produce more coronavirus tests. The company received an emergency use authorization in June for its rapid molecular test.
There is growing evidence that the coronavirus may be able to re-infect patients, and a new instance of a second infection has been confirmed in the US. It is the fifth confirmed reinfection worldwide after at least four other cases were confirmed in Belgium, the… Read More »Coronavirus re-infection case confirmed in the US
Medicare doesn’t currently cover drugs approved under emergency use designations. But CMS Administrator Seema Verma said the agency was coming up with a plan to make sure Medicare beneficiaries were covered once a coronavirus vaccine is developed.
The government’s three-tier COVID-19 alert system has left GPs and at-risk patients facing major uncertainty as the pandemic’s second wave grows, the BMA has warned.
In comments recently submitted to the administration, PhRMA raised concerns with a number of changes included in the Centers for Medicare & Medicaid Services (CMS) Medicaid proposed rule. Today, we’re diving deeper into CMS’s proposal to vastly expand the types of medicines that would fall… Read More »Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
The government has confirmed that shielding rules could be re-imposed in areas worst-hit by COVID-19 for a ‘limited period’.
The assurances come amid concerns that the Trump administration would brush aside scientific expertise in its push for a vaccine ahead of the election on Nov. 3.
Company is unclear about whether patient was receiving vaccine or placebo in 60,000-patient study Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed. The pharmaceutical giant was unclear if the patient was administered a… Read More »Johnson & Johnson pauses Covid vaccine trial over participant’s ‘unexplained illness’
The government plans to roll out routine COVID-19 testing for asymptomatic NHS staff in areas where the virus is spreading fastest – and hopes to expand this to GPs, NHS England’s medical director has said.
Regeneron has followed Eli Lilly in asking the FDA for emergency approval of its COVID-19 antibody therapy, shortly after the drug was thrust into the spotlight by being used to treat President Trump. The request for emergency use authorization (EUA) for REGN-COV2 comes amid a… Read More »Regeneron joins Lilly in seeking emergency OK for COVID-19 antibody
The European Commission has taken its advance orders for potential COVID-19 vaccines to more than 1.1 billion, after signing a supply deal for up to 400 million doses of Johnson & Johnson’s experimental candidate. The agreement is the third for coronavirus vaccine supply for the… Read More »EU ramps up supply of COVID-19 vaccine, drugs
Because the prevalence of depression and anxiety disorders appears to have increased substantially since the start of the Coronavirus pandemic, if the ACA is repealed, mental illnesses could be the most common pre-existing conditions.
LMCs are fighting back over damaging claims about GPs’ response to the COVID-19 pandemic – warning MPs that the profession has ‘never faltered or stopped’ and collecting data to demonstrate the strain practices are under.
Eli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing new efficacy data from an ongoing trial. It’s been a big week for this class of therapies – Regeneron’s antibody cocktail was famously used to treat president… Read More »Lilly asks FDA for emergency clearance for COVID-19 antibody therapy
The UK has been leading research into the COVID-19 outbreak, according to the country’s pharma trade body, but there needs to be a strategy to restart trials into other diseases. The Association of the British Pharmaceutical Industry (ABPI) said that restarting research into diseases such… Read More »Government needs strategy to kick-start R&D after COVID, says pharma body
The company announced data on the combination of two antibodies against the SARS-CoV-2 virus, showing significant reductions in viral load compared with placebo. The company has applied for an EUA for LY-CoV555 and will seek an authorization for the combination of that drug with LY-CoV016… Read More »Lilly seeks emergency clearance for Covid-19 monoclonal antibodies on Phase II data
NHS England has unveiled plans to offer patients experiencing long COVID symptoms support from GPs and other health professionals at specialist clinics across the country.
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients… Read More »The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
The guidance calls for a median two months’ worth of follow-up safety data from well-designed Phase III studies as a precondition for a vaccine receiving an EUA. The Wall Street Journal reported that the White House had backed down in its opposition to the guidance,… Read More »FDA issues Covid-19 vaccine guidance as White House reportedly relents
Shots: GSK will make equity investment to gain access to Vir’s technology of $250M, priced at $37.73 (a 10% premium to closing share price on March 27, 2020). The equity investment and collaboration will complete at the same time & are conditional upon customary conditions… Read More »GSK Signs an Agreement with Vir Biotechnology to Develop Solutions for Coronaviruses
Supplies of swabs for coronavirus and other critical NHS tests for diseases like cancer, diabetes and heart disease have been threatened by a failure at a facility operated by Roche. The company said the problems – which also include other items like reagents and screening… Read More »Roche working “around the clock” to tackle UK test supply problems
Supplies of swabs for coronavirus and other critical NHS tests for diseases like cancer, diabetes and heart disease have been threatened by a failure at a facility operated by Roche. The company said the problems – which also include other items like reagents and screening… Read More »Roche working “around the clock” to tackle UK test supply problems
GlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting heat on Regeneron’s rival that has been famously used to treat president Donald Trump. GSK and Vir began trials of the antibody on early-stage COVID-19 patients in… Read More »GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rival
The FDA may have been blocked from issuing stricter guidelines for emergency approval of COVID-19 vaccines by the Trump administration, but it has still managed to make its new approach public. The regulator published “advice” to vaccine developers as part of documentation prepared for a… Read More »FDA gives COVID-19 vaccine ‘advice’ after White House blocks guidance
While payers and policymakers took a more narrow-minded perspective on innovation value in 2020, the year 2021 will bring an increased focus on a treatment’s societal value, how innovation interacts with digital technologies, and whether new innovations are able to reduce existing health outcome inequalities.
Members of the House and Senate have seen the need to boost the national stockpile with PPE that is made in America. Failure to do so would only exacerbate the problems when our healthcare system is stretched thin.
An Excel spreadsheet was behind IT glitch that caused thousands of positive COVID-19 tests to be omitted from the UK’s official records, according to press reports. The issue that left almost 16,000 positive results going unreported has been blamed on the way Public Health England… Read More »Excel spreadsheet blamed for UK’s COVID-19 test and trace woes
While the White House and doctors at Walter Reed have sought to reassure the public that Trump’s condition is improving, he has received numerous drugs for Covid-19, including the steroid dexamethasone, which is typically administered only to those who are critically ill.
New guidance on the persistent effects of COVID-19 on patients, or long COVID, is to be developed by NICE, SIGN and the RCGP.
The government must give greater consideration to indirect COVID-19 harms when making decisions about ongoing restrictions or risk a ‘myriad’ of long-term health issues, GPs have warned in a letter to health secretary Matt Hancock.
The company said it was meeting real-time supply demands for Veklury (remdesivir) in the U.S. and anticipated meeting global demands for the drug worldwide. AmerisourceBergen will continue acting as sole U.S. distributor.
European regulators have started a first ‘rolling review’ of a COVID-19 vaccine, which is being developed by AstraZeneca in collaboration with the University of Oxford. It’s an historic announcement, bringing hope that the vaccine could be approved in the near future, although the European Medicines… Read More »European regulators begin rolling review of AZ’s COVID-19 vaccine
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections.
Reuters reported Wednesday that U.S. regulators would look at data from previous clinical trials that came from the same scientists who created the vaccine, AZD1222, which originated at the University of Oxford and is also known as ChAdOx1 nCoV-19.
Biopharmaceutical researchers are at the heart of a robust American research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world.
The rapid spread and impact of COVID-19 has sparked a global race to find effective treatments and preventative vaccines with the U.S. biopharmaceutical industry leading the charge. America’s biopharmaceutical companies are working together in unprecedented collaboration, to defeat COVID-19 by developing the innovative tests, treatments,… Read More »Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
The company published interim data from the Phase I study of mRNA-1273 in 40 older and elderly adults, showing responses comparable to those seen in younger adults. The vaccine is being tested in a 30,000-participant Phase III trial.
MPs have demanded urgent action to prevent avoidable harm to patients from the NHS backlog triggered by the COVID-19 pandemic – and set a one-month deadline for the government to explain its failure to roll out routine testing for healthcare staff.
The company said that those who received the two-antibody cocktail REGN-COV2 showed a lower viral loads and faster alleviation of symptoms than those who received placebo.
GP practices will be unable to cope with a second wave of COVID-19 unless urgent measures are put in place to support family doctors and their teams, the BMA has warned.
Date: October 19, 2020 Issue #: 1609 Summary: Remdesivir (Veklury – Gilead), an investigational antiviral drug administered by IV infusion, is now available through an FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in all hospitalized patients. An earlier EUA limited use of the… Read More »Timing of Remdesivir for COVID-19
The government has outlined plans to provide ‘an uninterrupted supply’ of PPE during winter, but GPs remain in the dark about how they will be reimbursed for items bought during the first coronavirus wave.
Older adults living in care homes and staff working there will be first to receive COVID-19 vaccinations under updated government advice – with health and social care workers and people over 80 next in line.
Older adults living in care homes and staff working there will be first to receive COVID-19 vaccinations under updated government advice – with health and social care workers and people over 80 next in line.
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections.
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing potential therapeutics to treat COVID-19 and vaccines to prevent future infections.
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we… Read More »Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
We’ve seen the scientific community come together time and again throughout the COVID-19 pandemic, and we’re thrilled to have been part of a hackathon bringing together data scientists, epidemiologists and partner organizations focusing on analysing the hypothesis of whether the tuberculosis (TB) vaccine – BCG… Read More »BCG-COVID 19 Hackathon: Task 1 winners announced, Task 2 – data scientists – we need you!
Figure 1. Classification of COVID-19 Disease States.Adapted from Sidiqi, H.K. and M.R. Mehra, COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant, 2020. [1] (This piece was co-authored by Prof. Gordon Broderick, Clinical Systems Biology at Rochester General Hospital.) The thing… Read More »Modeling Coronavirus – Cytokine Storm
The post ‘There was a lot of death and suffering’: How soldiers turned the tide in Ontario’s long-term care homes appeared first on Healthy Debate.
Government plans to change vaccine rules as the NHS prepares to deliver its largest-ever flu campaign and a potential COVID-19 vaccine could see a wider range of staff allowed to administer jabs.
We are living through an extraordinary moment as COVID-19 continues to spread across the United States. During this time, frontline and essential workers across industries have bravely stepped up to meet the urgent needs of our society: from the emergency room to the supermarket to… Read More »The 2020 We Work for Health Champion Awards showcase the best of our industry
Despite the UK’s world class research output and the many start-ups successfully spinning out from its academic institutions, in recent years UK biotech companies have struggled to access the capital they need to scale up and make their mark on the industry. The COVID-19 pandemic… Read More »COVID-19 is causing a renaissance in the UK biotech sector, we must ensure it lasts
The drug, AZD7442, is designed to potentially provide at least six months of protection from Covid-19. The trial, which is funded by federal defense and health authorities in the U.S., is enrolling up to 48 healthy volunteers in the U.K. AstraZeneca’s double-antibody approach is similar… Read More »AstraZeneca starts Phase I study of long-acting double-antibody cocktail for Covid-19
Alnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing and how it could offer a route to target the current coronavirus pandemic. Brendan joined Alnylam in 2016 as one of the company’s first Europe-based employees and… Read More »Alnylam, gene-silencing and biotech in 2020: the pharmaphorum podcast
The study, by researchers at Harvard, MIT, The Broad and other institutions, used genomic analysis of cases linked to the Biogen meeting, linking much of the community transmission in the Boston area to a European genetic variant of SARS-CoV-2 that first appeared at the meeting.
Janssen’s Anouk De Vroey on why we need to extend the public/private partnerships resulting from COVID-19 into more high-level dialogue on health innovation with governments. Friday 13th March 2020 – I am not a superstitious person in general, but I will never forget that particular… Read More »Time for a health innovation pact: rethinking the design and delivery of healthcare
The FDA commissioner took to Twitter Monday night to defend his performance at the agency, which came under sharp criticism amid accusations that the authorization of a plasma treatment for Covid-19 was politically motivated and that he stood by while President Trump unfairly maligned FDA… Read More »Stephen Hahn and the terrible, horrible, no good, very bad FDA weekend
The biotech company reached a deal with the European Commission to supply an initial 80 million doses, while European Union member states will have the option to purchase 80 million more.
The first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that are being developed to both treat and prevent coronavirus infections. The phase 1 trial – funded by the US government – will take place in the UK… Read More »Chasing Regeneron, AZ starts trials of its COVID-19 antibody cocktail
While the emergency use authorization granted Sunday was not seen as scientifically unwarranted, it drew concerns from some experts that it could hinder enrollment in clinical trials, while the timing and circumstances of the FDA’s move fueled suspicions that political pressure – rather than science… Read More »FDA’s emergency authorization for convalescent plasma in Covid-19 sparks controversy
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients… Read More »The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
Over the weekend, Trump called the agency, without evidence, part of a “deep state” that was slow-walking vaccines and drugs for Covid-19. The next day, the agency authorized convalescent plasma despite having turned it down shortly before due to insufficient evidence.
The FDA has allowed a blood plasma treatment for COVID-19 to be administered under an Emergency Use license – but some have decried the move as a “political stunt” as president Trump accuses the agency of impeding progress on coronavirus therapies. The convalescent plasma treatment… Read More »COVID plasma treatment gets emergency license from FDA after Trump criticism
China has already granted emergency use authorisation to multiple COVID-19 vaccines developed by domestic drugmakers and started dosing key workers, according to local media reports. Zheng Zhongwei, head of China’s COVID-19 vaccine development task force, made the revelation on Chinese television, saying that the vaccines… Read More »Chinese starts vaccinating key workers against COVID-19; report
The companies also said their Phase II/III study, slated to enroll about 30,000 participants, had already dosed more than 11,000.
Doctors have called for rules to be tightened on coronavirus antibody tests in the UK amid fears that false readings could put the public at risk. It’s not even known for sure that having antibodies against the SARS-CoV-2 coronavirus confers immunity. But with many other… Read More »UK doctors call for tighter rules on coronavirus antibody tests
Once people recognized that the situation would be more than just a transient window, a growing number of healthcare and life sciences organizations took steps to deploy consistent and secure solutions to digitize a wide range of traditionally paper processes.
As the summer of 2020 starts to creep to a close, America’s biopharmaceutical research companies are working around the clock to identify new treatments to reduce COVID-19 infection and vaccines, to prevent symptoms. The rate of advancement of therapeutics and vaccines has been unprecedented with… Read More »Summer reading in the age of COVID-19
New insights into smell and taste loss symptoms, artificial intelligence and further encouraging data from a vaccine candidate hit the headlines this week as the COVID-19 coronavirus pandemic continues. Here we highlight the biggest R&D, market access and digital coronavirus news of the past week.… Read More »Coronavirus pharma news round-up 21/08/20
Pfizer and BioNTech have said their COVID-19 vaccine could be ready for regulators to review by October and approved by the end of the year after releasing more favourable data from an early-stage trial. There are no vaccines approved for COVID-19 and governments across the… Read More »Pfizer/BioNTech say COVID-19 jab on track for approval by year-end
The New York Times reported that the FDA was prepared to issue an emergency use authorization for the treatment last week, but NIH Director Francis Collins and NIAID Director Anthony Fauci intervened, arguing that data were too weak.
NHS England medical director for primary care Dr Nikki Kanani has defended the efforts of GPs during the COVID-19 pandemic – hitting back at claims that practices had shut their doors to patients.
Roche has agreed to help Regeneron manufacture its COVID-19 antibody cocktail REGN-COV2, which started late-stage clinical testing a few weeks ago, in a deal that could more than triple supplies of the drug if it gets approved. Regeneron is already working on ramping up manufacturing… Read More »Regeneron recruits Roche to make COVID-19 antibody drug REGN-COV2
The deal brings Roche’s considerable manufacturing heft to Regeneron’s efforts to develop the two-antibody cocktail, REGN-COV2. Regeneron will distribute the drug in the U.S., while Roche will distribute it ex-U.S.
Smell and taste loss associated with COVID-19 differs from that experienced by patients with common colds or flu, according to researchers who said the symptom could be used to quickly identify coronavirus infections in settings such as airports or emergency departments. The study published in… Read More »Smell and taste loss could help identify COVID-19 at airports, say researchers
The UK government has said it is vital to adopt telemedicine across the NHS in response to COVID-19 – but is the health service ready to fully embrace this digital tech? Dom Tyer investigates. The rapid digitalisation of life during COVID-19’s acute phase has had… Read More »NHS’ telemedicine ambitions approach a pivotal point
Public Health England has been scrapped less than six months after the COVID-19 pandemic began as the government announced it would be ‘brought together’ with the NHS test and trace programme and the UK’s Joint Biosecurity Centre.
Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses? This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. The Corona Accelerated… Read More »Could AI avert a future coronavirus pandemic?
Pharma companies have improved how they engage with healthcare providers as a result of COVID-19, according to a new survey of HCPs. This has resulted in pharma companies being more relevant and providing more value in closing the care gap, the report says. The Accenture… Read More »Pharma improves HCP engagement during COVID-19 – report
Shares in Netherlands biotech Kiadis rose sharply on the news that it would start developing a natural killer (NK) cell therapy for COVID-19, but later lost most of the gains on what looks like profit-taking. Kiadis has joined forces with five Dutch biomedical groups on… Read More »Kiadis shares yo-yo on cell therapy trial for COVID-19
Health Secretary Matt Hancock is planning to dissolve Public Health England and replace it with a new agency dedicated to responding to pandemics, according to reports. The plan is to implement a new body modelled on the independent Robert Koch Institute in Germany, which has… Read More »Government under fire over plan to scrap Public Health England
The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. ChAdOx1 – which is in large-scale phase 2/3 trials –… Read More »EU places firm order for AZ/Oxford Uni’s ChAdOx1 COVID-19 vaccine
Earlier this month, Ohio Gov. Mike DeWine received a false-positive result from a rapid antigen test for Covid-19, raising concerns about the tests’ accuracy. The assay’s maker, Quidel, said it is investigating the case.
As virtual care is only going to grow in the coming months as a solution to pent-up demand for care that has resulted from the pandemic, focused attention is needed to address these operational and reimbursement issues.
The company plans to train 250 new racially and ethnically diverse clinical trial investigators and extend the reach of its trials to underserved rural and urban communities.
Catch up on the latest coronavirus vaccine and digital tech news in our roundup of this week’s biggest stories. Consumer advocacy group Public Citizen has slammed the amount Moderna is charging the US for the mRNA-1273 vaccine, saying that as taxpayer money had funded 100%… Read More »Coronavirus pharma news roundup – 14/08/20
The UK is to buy millions more doses of potential coronavirus vaccines from Johnson & Johnson and Novavax, with the latter expanding its manufacturing operation in the country. Johnson & Johnson’s Janssen pharmaceuticals unit will supply an initial 30 million doses on a not-for-profit basis… Read More »UK signs coronavirus vaccine deals with J&J and Novavax
After ditching its home-grown attempt at a coronavirus contact-tracing app for smartphones, the UK is ready to start pilot trials of a second version based on a platform developed by Apple and Google. The new NHS Test and Trace app is intended to be used… Read More »UK’s second go at a contact tracing app heads for pilot study
Patients who refuse to wear a face covering when attending a GP practice could be told they will be seen via remote consultation instead, under official NHS guidance.
Taylor lifts heavy, is in their first year of med school, and still finds time to complete Quest Squad missions. Be like Taylor.
Just under 6% of England’s population – around 3.4 million people – had been infected with coronavirus by the end of June according to an estimate based on antibody tests. More than 100,000 people tested themselves for antibodies against the SARS-CoV-2 virus that can lead… Read More »Around 3.4m people infected with coronavirus in England – study
More than one in five GPs may have had COVID-19, according to a BMA survey that shows doctors are increasingly treating patients for potential long-term symptoms of the virus.
Dr. Jim Merlino, Chief Clinical Transformation Officer, Cleveland Clinic Despite having entered the US eight months ago, COVID-19 remains a topic enshrouded in confusion, conflicting information, hyperbole, and even conspiracy theories. Everyone, informed or not, seems to have an opinion about the coronavirus pandemic. Fortunately,… Read More »[Podcast] How Cleveland Clinic Helps Employers Create a Safer Workplace During COVID-19
The US government has signed another big coronavirus vaccine supply deal, snapping up 100 million doses of Moderna’s mRNA jab for a little over $1.5 billion –around $15 per dose or $30 per course. That’s a steep discount on the $32 to $37 price per… Read More »Anger at US deal for Moderna’s ‘taxpayer-funded’ COVID-19 vaccine
In a commentary, physicians and pharmacists wrote that percentages of Black, Latino and Native American patients in two Phase III studies of the drug that the company is using for FDA approval were disproportionate to Covid-19’s incidence in those communities.
The agreement, which includes 100 million doses of mRNA-1273 and an option to acquire 400 million more, brings the total amount of money the biotech company has received from the federal government for its vaccine efforts to nearly $2.5 billion.
As PhRMA members work around the clock to combat COVID-19, the pandemic has had a tremendous impact around the globe. But for those patients who are currently impacted by a health care condition, COVID-19 has been particularly challenging. Whether immunocompromised, actively receiving treatment or battling… Read More »The patient perspective navigating COVID-19
The potential that wearables have for helping detect early signs of Covid-19 and other infectious diseases, as well as monitoring patients, will make this technology a popular choice for healthcare organizations and consumers for the foreseeable future.
Russian President Vladimir Putin said a vaccine developed at a Moscow research institute that appears to still be in Phase I development among fewer than 100 participants had undergone all necessary tests.
Russia has become the first country in the world to approve a coronavirus vaccine, amid scepticism from international experts who have been unable to review or verify clinical data from the jab called ‘Sputnik V’. According to press reports the vaccine has been tested on… Read More »Scepticism as Russia claims coronavirus vaccine breakthrough with Sputnik V
Drugmakers have been working with data specialist Certara on a new tool that they hope could speed up the development of vaccines for COVID-19. The new “biosimulation” tool is designed to make it easier for vaccine candidates across multiple patient populations through the use of… Read More »Certara adds to its COVID-19 toolkit with virtual trials module
Gilead has filed its COVID-19 drug remdesivir with the FDA, to treat patients with severe disease, under the brand name Veklury. The drug is currently available to US patients under an Emergency Use Authorisation for treatment of hospitalised patients with severe COVID-19. This filing is… Read More »Gilead files COVID-19 drug remdesivir with FDA
Swiss medical data specialist Sophia Genetics has launched a platform that will sift through data generated at more than 1,000 hospitals around the world to try to work out how the COVID-19 pandemic will evolve in the coming months and years. The data mining tool… Read More »Sophia Genetics launches AI tool to find COVID-19 ‘unknowns’
Gilead Sciences had said in its second-quarter earnings that it would partner with companies in North America, Europe and Asia to manufacture the antiviral drug, which received an emergency use authorization from the FDA in May.
The annual healthcare budgeting process begins with forecasting future patient volumes, case mix, and revenue. […]
Pfizer has signed a multi-year agreement with Gilead to manufacture and supply the COVID-19 antiviral remdesivir, which is also being tested in combination with other drugs in an effort to fight the pandemic. Under the terms of the agreement Pfizer will become one of several… Read More »Pfizer signs deal with Gilead to manufacture COVID-19 antiviral remdesivir
Pharma’s reputation has soared due to the COVID-19 pandemic – but coronavirus is starting to bite companies’ sales. Find out more in our roundup of the biggest R&D, market access and digital stories from the past week. The perception of pharma and medical companies has… Read More »Coronavirus pharma news roundup – 07/08/20
The drug has consistently failed to show a benefit when tested in randomized, controlled clinical trials. Social science may explain why laypeople and doctors alike continue clinging to it.
Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by year-end. The US biotech is gearing up to produce two billion doses of the vaccine… Read More »Novavax says COVID-19 vaccine could be approved by year-end
The current level of test and trace in the UK is inadequate to prevent a sharp increase in coronavirus infections when schools reopen in September and there is further relaxation of social distancing rules, according to scientists. A second wave of COVID-19 could be avoided… Read More »Government warned over test and trace as UK schools prep to reopen
In this episode of MedCity Pivot podcast, we discuss Zeke Emanuel’s book where he asks the question – which country has the best healthcare in the world – and of course policy, politics, Covid-19. And his grandmother.
A third of single-handed GPs are at high-risk from COVID-19, which could potentially leave thousands of patients without access to face-to-face appointments, new research suggests.
A third of single-handed GPs are at high-risk from COVID-19, which could potentially leave thousands of patients without access to face-to-face appointments, new research suggests.
A third of single-handed GPs are at high-risk from COVID-19, which could potentially leave thousands of patients without access to face-to-face appointments, new research suggests.
Health information exchanges know about the hard work of building trust by delivering value in healthcare. They have been in these trenches. They need a seat at the table with our state public health leaders as America works to safely reopen.
Under the agreement with BARDA and the Department of Defense, the drugmaker would supply 100 million doses of its vaccine, for which it published preclinical data last and is currently running a first-in-human clinical trial.
The UK digital mental health support platform Kooth has joined with five of the UK’s well known Instagram influencers to launch a campaign to help students deal with the pressures of exam results season. The campaign encourages the hundreds of thousands of students waiting to… Read More »Mental health platform helps students facing exam results during pandemic
NHS England has released details on how practices can claim back additional costs incurred during the pandemic, but warned they may have to pay back any funding they have already received if it falls outside the guidance.
NHS England has released details on how practices can claim back additional costs incurred during the pandemic, but warned they may have to pay back any funding they have already received if it falls outside the guidance.
NHS England has released details on how practices can claim back additional costs incurred during the pandemic, but warned they may have to pay back any funding they have already received if it falls outside the guidance.
America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make significant progress toward identifying solutions to diagnose, treat and prevent infections from the virus.
Bayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion net loss made worse by lower sales in its pharma and consumer health divisions. Group sales were down 2.5% to just over €10 billion, with pharma falling… Read More »Bayer slides on €9.5bn loss caused by litigation, COVID-19 impact
While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations. The US drugmaker is testing the antibody – called LY-CoV555 and developed in collaboration with Canadian… Read More »Lilly’s antibody for COVID-19 protection starts nursing home trial
Three of the companies making drugs used in the Phase II I-SPY COVID-19 study – Amgen, AbbVie and Takeda – announced the patient enrollments Monday. The study, which will enroll up to 1,500 critically ill patients, could test around 10 drugs.
The Covid-19 pandemic is providing the impetus to look at the senior home health care model differently and more holistically.
Financial terms of the deal were not disclosed, but it follows a $1.95 billion contract between the two companies and the U.S. government. Assuming clinical trial success and regulatory approval, they would supply the vaccines in early 2021, ahead of the rescheduled Tokyo Olympics.
The US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 vaccine development initiative, committing up to $2.1 billion for an initial 100 million doses. The collaborative effort with the US government will accelerate the development and manufacturing… Read More »US pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-19 vaccine
The companies will provide 100 million doses of their jointly developed vaccine. But with a Phase I/II study planned in September, it is behind in development compared with those of Moderna and Pfizer and BioNTech, which have already started late-stage clinical testing.
Vaccines, AI-driven drug discovery and llamas all hit the headlines this week as the search for a way to end the COVID-19 pandemic continues. Here we highlight the biggest R&D, market access and digital coronavirus news of the past week. Roche’s anti-inflammatory drug Actemra has… Read More »Coronavirus pharma news roundup – 31/07/20
Gilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – but revenues are declining as the pandemic bit into sales of its hepatitis C drugs. Product sales in Q2 were down nearly 10% compared with last year… Read More »Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisition
GPs and other healthcare professionals in England will now be required to self isolate for 14 days if they are returning from any country deemed high-risk for COVID-19, the government has said.
GPs and other healthcare professionals in England will now be required to self isolate for 14 days if they are returning from any country deemed high-risk for COVID-19, the government has said.
GPs and other healthcare professionals in England will now be required to self isolate for 14 days if they are returning from any country deemed high-risk for COVID-19, the government has said.
In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans afford their medicines, he instead declared war on medical innovation. Our nation’s priority should be beating… Read More »Executive order threatens R&D when we need it most to fight COVID-19
People with COVID-19 symptoms or a positive test result should now self-isolate for 10 days, instead of seven, the UK government has said.
People with COVID-19 symptoms or a positive test result should now self-isolate for 10 days, instead of seven, the UK government has said.
People with COVID-19 symptoms or a positive test result should now self-isolate for 10 days, instead of seven, the UK government has said.
AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 pandemic. AZ’s second quarter sales increased by 8% compared with the same period last year to just under $6.3 billion.… Read More »AstraZeneca beats expectations in Q2, while GSK struggles during pandemic
Donald Trump has launched another defence of hydroxychloroquine as a treatment for COVID-19 which goes against prevailing medical advice. The President’s comments came after Twitter banned his eldest son from tweeting for 12 hours, after he posted a video which repeated the assertion that hydroxychloroquine… Read More »Trump reiterates hydroxychloroquine defense after son is banned from Twitter
Novartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face of company culture, now and in the future. We also looked at how Novartis’ own operations had to change in response to the coronavirus pandemic and the… Read More »Novartis, company culture and COVID-19: the pharmaphorum podcast
While lockdown eases across England, local lockdowns are becoming an ever-growing threat across the country. This is a unique response in comparison to other countries across the world and could be indicative of a second spike in infections. At the beginning of the pandemic, The… Read More »Understanding COVID-19 and varying responses across the globe
The company said that the COVACTA trial of Actemra in Covid-19 pneumonia had failed to meet its primary endpoint. Earlier this month, Regeneron and Sanofi announced that their study of a similar anti-inflammatory drug had also not met its primary endpoint.
India registered its first COVID-19 case on 30-January-2020 in Kerala. The cases since then are on a continuous rise. The Government of India in order to contain the spread of novel coronavirus rolled out several guidelines and precautionary measures. The situation worldwide was so serious… Read More »In The Global Race For The COVID-19 Vaccine, India Stands As A Strong Player
Roche’s anti-inflammatory drug Actemra has failed in a phase 3 clinical trial that was testing to see if it improved the condition of patients with COVID-19 associated pneumonia. The COVACTA trial of Actemra (tocilizumab) did not meet its primary endpoint of improved clinical status, or… Read More »Setback in COVID-19 effort as Roche’s Actemra fails in key trial
The UK government has signed its fourth coronavirus vaccine deal, snapping up 60 million doses of an experimental shot being developed by Sanofi and GlaxoSmithKline. The order has come in even before the vaccine has started clinical development, with a phase 1/2 trial not due… Read More »UK places order for 60m doses of Sanofi/GSK’s COVID-19 vaccine
Belgium’s ExeVir Bio is to accelerate development of a new treatment for COVID-19 based on llama antibodies, after a 23 million euro ($27 million) financing round. ExeVir is a spin-out of Vlaams Instituut voor Biotechnologie (VIB), Belgium’s life sciences research institute and the company also… Read More »Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out
A major new research project, backed by £2.1m of government funding, is aiming to better understand the risks black, Asian and minority ethnic (BAME) healthcare workers face from COVID-19.
A major new research project, backed by £2.1m of government funding, is aiming to better understand the risks black, Asian and minority ethnic (BAME) healthcare workers face from COVID-19.
A major new research project, backed by £2.1m of government funding, is aiming to better understand the risks black, Asian and minority ethnic (BAME) healthcare workers face from COVID-19.
The companies said they had started a Phase II/III trial BNT162b2. The news comes the day after Moderna announced the launch of its Phase III study and days after Pfizer and BioNTech signed a nearly $2 billion vaccine supply deal with the federal government.
Hydroxychloroquine, the anti-malaria drug controversially used to fight COVID-19, was trending again after a string of retweets from president Donald Trump in favour of the medicine. Trump has championed hydroxychloroquine, which was first touted as a potential cure for COVID-19 by the French doctor Didier… Read More »Trump’s tweets advocate hydroxychloroquine as big COVID-19 vaccine trials start
New research from MHP Health and ComRes looks at what impacts COVID-19 has had on the public’s health data sharing concerns, and asks how the industry can maintain confidence in data usage after the pandemic. In April, at the beginning of the COVID crisis, the… Read More »Brits more comfortable sharing data with pharma since COVID-19 – survey
US biotech AI Therapeutics has begun a phase 2 trial of its LAM-002A, an antiviral drug that has shown promise against the SARS-CoV-2 coronavirus in the lab. The company develops drugs that have been identified with a proprietary artificial intelligence (AI) algorithm that matches drugs… Read More »US biotech uses AI to pick antiviral for COVID-19 trial
Providing access to multiple sources of sensitive data to enable key functions like contract tracing and monitoring hospitalizations also means increased vulnerabilities and the emergence of entirely new attack surfaces.
The company had received $483 million from BARDA in April to fund the development of the vaccine, mRNA-1273, through Phase III, but that amount was based on a smaller anticipated number of participants than the 30,000 it now plans to enroll into the trial, named… Read More »Moderna snags another $472M from BARDA, launches Phase III Covid-19 vaccine trial
A US government agency is to give a further $472 million to biotech Moderna, after it announced plans to expand a phase 3 trial for its potential COVID-19 jab. The latest funding from the Biomedical Advanced Research and Development Authority follows a tranche worth $483… Read More »Moderna gets further $472m as expanded phase 3 COVID-19 trial begins
The study adds to the growing body of evidence that the drug, promoted early in the pandemic by President Trump, is ineffective, despite its getting a briefly renewed lease on life earlier this month thanks to a retrospective analysis.
A successful cocktail would also serve us in the long-run to treat the impacts of Covid-19 and keep those who are most vulnerable, the elderly and those with pre-existing conditions, more resilient against serious illness or death.
GPs, staff in clinical and non-clinical roles and patients should wear a mask or face covering in practices if premises cannot be made ‘COVID-secure’, updated Public Health England (PHE) guidance warns.
GPs, staff in clinical and non-clinical roles and patients should wear a mask or face covering in practices if premises cannot be made ‘COVID-secure’, updated Public Health England (PHE) guidance warns.
GPs, staff in clinical and non-clinical roles and patients should wear a mask or face covering in practices if premises cannot be made ‘COVID-secure’, updated Public Health England (PHE) guidance warns.
GPs, staff in clinical and non-clinical roles and patients should wear a mask or face covering in practices if premises cannot be made ‘COVID-secure’, updated Public Health England (PHE) guidance warns.
With coronavirus vaccine trials finally showing positive results, analysts are starting to wonder what access challenges might lie ahead. We highlight the top R&D, digital and market access news for COVID-19 from the past week. Data from more than 1,000 healthy volunteers dosed with a… Read More »Coronavirus pharma news roundup – 24/07/20
UK manufacturing exports fell sharply during the second quarter as the COVID-19 pandemic gathered pace, but pharma and healthcare products were much less affected, says a Lloyds Bank report. The latest quarterly UK International Trade Index reveals that the Chemicals and Plastics sector – which… Read More »UK pharma resilient in 2Q, despite pandemic fallout
The Research Data Alliance (RDA) has released its final version of the RDA COVID-19 Recommendations and Guidelines on data sharing for COVID-19, which covers four main research areas: clinical data, omics practices, epidemiology and social sciences. The document also touches on issues like community participation,… Read More »Research Data Alliance Releases Guidelines for COVID-19 Data Sharing
MedCity spoke with Evidation and BrightInsight, two startups that have recently announced funding rounds, amid a Covid-19 pandemic worsening in the U.S.
The company said the CareStart Covid-19 MDx RT-PCR test is designed to detect RNA from the SARS-CoV-2 virus and produce results within 83 minutes.
As the UK’s economy is hit by its worst contraction for 41 years, an influential committee of MPs has blasted the government’s failure to plan for the economic impact of a pandemic and stock up on protective equipment for health staff. The Commons Public Accounts… Read More »Influential MPs ‘astonished’ at UK government’s delayed pandemic response
The US government has agreed to pay Pfizer and BioNTech $1.95 billion to secure access to 100 million doses of their coronavirus vaccine on approval, just days after promising results in a clinical trial. The deal – part of the Trump administration’s Operation Warp Speed… Read More »US places $1.95 billion order for Pfizer/BioNTech’s COVID-19 vaccine
The companies will supply 100 million doses of the vaccine by the end of the year, and the government will have the option to acquire 500 million more. However, the FDA must grant an authorization based on its safety and efficacy, for which there are… Read More »Pfizer, BioNTech get $1.95B from HHS to supply Covid-19 vaccine
We believe the areas that will require the most adaptation are in value-based care payment models, digitally integrated and tailored care delivery and automation.
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients… Read More »The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
David Peacock has worked across the world for MSD and other companies, and has now taken the helm of MSD’s UK & Ireland operations. In the latest article in our UK Leaders series, he tells us about the opportunities and challenges he is excited to… Read More »MSD’s David Peacock on moving UK healthcare forward
Concerns have emerged about access to some potential COVID-19 vaccines after pharma executives from three companies said they expect to make profits from their products in evidence to a US Congressional panel. Moderna, Merck & Co, and Pfizer said they expect to profit from coronavirus… Read More »Controversy as pharma execs predict profits from COVID-19 vaccines
Healthware has launched a new online resource that aggregates information and analysis on how to respond to the huge changes COVID-19 has wrought across life sciences and healthcare. The open access newnormal.health aims to help guide executives from pharma, biotech and medical device companies in… Read More »Healthware launches global resource hub for COVID-19’s ‘new normal’
The COVID-19 pandemic is spreading to every corner of the world. During this worldwide attack of virus, human beings are highly concerned for their immune system, since it is the only savior currently. In circumventing a response to pathogenic infections like coronavirus, a healthy microbiome… Read More »Healthy Microbiome: Fighter Against COVID-19
“Everybody’s an infectious disease company now,” ARCH Venture Partners Managing Director Bob Nelsen said. By contrast, a report last year showed a huge decline in venture capital investment in the infectious disease space.
Flu jabs could take twice as long to deliver this year as practices grapple with COVID-19 social distancing measures, RCGP guidance warns.
Flu jabs could take twice as long to deliver this year as practices grapple with COVID-19 social distancing measures, RCGP guidance warns.
Flu jabs could take twice as long to deliver this year as practices grapple with COVID-19 social distancing measures, RCGP guidance warns.
Throughout history, infectious diseases caused by pathogens such as bacteria or viruses have taken a devastating toll on the lives and security of people around the world. With the ongoing COVID-19 pandemic gripping the world, we are experiencing a challenging situation that we haven’t seen… Read More »New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
JP Morgan has downgraded its valuation of Moderna, saying its $37 billion market cap is way too high even if its COVID-19 vaccine mRNA-1273 succeeds in clinical trials. Moderna’s share price has rocketed 385% this year, driven by the development of mRNA-1273, but the analysts… Read More »Moderna’s $37B market cap is too high, despite COVID-19 vaccine; analyst
Leaving GP practices out of the NHS COVID-19 track and trace system is a mistake that has left the UK government operating with ‘three layers of mittens on’, a leading US health expert has warned.
Leaving GP practices out of the NHS COVID-19 track and trace system is a mistake that has left the UK government operating with ‘three layers of mittens on’, a leading US health expert has warned.
Leaving GP practices out of the NHS COVID-19 track and trace system is a mistake that has left the UK government operating with ‘three layers of mittens on’, a leading US health expert has warned.
Leaving GP practices out of the NHS COVID-19 track and trace system is a mistake that has left the UK government operating with ‘three layers of mittens on’, a leading US health expert has warned.
A COVID-19 vaccine developed by scientists at Oxford University appears safe and induces a strong immune response in healthy adults, according to preliminary results of a phase I/II trial.
A COVID-19 vaccine developed by scientists at Oxford University appears safe and induces a strong immune response in healthy adults, according to preliminary results of a phase I/II trial.
At MedCity INVEST, Mass General Brigham Chief Information Officer Chris Coburn shared how the health system prepared itself for Covid-19 by scaling up its digital operations.
The company said that patients receiving the drug, SNG001, had a 79% lower risk of requiring ventilation or dying compared with those on placebo, sending the company’s stock soaring more than 400%, but it did not clarify what that meant in terms of patient numbers.
Data from more than 1,000 healthy volunteers dosed with a coronavirus vaccine developed at Oxford University and AstraZeneca suggest the shot is safe and stimulates an immune response against the virus. The first phase 1/2 results with the ChAdOx1 vaccine – also known as AZD122… Read More »‘Promising’ data on Oxford/AZ, CanSino coronavirus vaccines
The company announced the publication of interim data from the Phase I/II study of a vaccine it is developing with the University of Oxford. The news comes the week after Moderna announced the publication of data for its vaccine.
A smartphone app developed by medical software specialist Allm is being trialled in Japan to see if it can help patients with milder coronavirus symptoms recuperate at home, without tying up healthcare resources. The app – called MySOS – provides “non-contact body monitoring”, harnessing artificial… Read More »Japan trials app to help coronavirus patients recover at home
An inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more serious stages of the disease. Southampton-based Synairgen said in a preliminary trial readout that the company’s SNG001 – an inhaled formulation of interferon beta – reduced risk of progression… Read More »Synairgen’s inhaled drug cuts chances of COVID-19 progressing
Now more than ever, it’s incumbent on us to use our vast presence in communities across the country to support organizations and the economy.